Literature DB >> 12659170

Phenobarbital pre-treatment prevents kainic acid-induced impairments in acquisition learning.

L M Brown-Croyts1, P W Caton, D T Radecki, S L McPherson.   

Abstract

This study examined the protective effect of phenobarbital on kainic acid-induced deficits in acquisition learning. A single kainic acid injection (9 mg/kg i.p.) was administered five days prior to testing using the Morris water maze test. Kainic acid produced deficits in the acquisition of spatial information observed as an increase in latency to a hidden escape platform. Daily phenobarbital treatment (20 mg/kg i.p.) initiated 45 minutes prior to the kainic acid injection blocked the kainic acid-induced deficits in acquisition learning. When daily phenobarbital treatment was initiated 2-3 hours after kainic acid seizure development it did not block the kainic acid induced-deficits in water maze performance. Daily administration of phenobarbital alone at the moderate concentration used in this study did not cause alterations in behavioral performance in the Morris water maze. These studies indicate that phenobarbital pre-treatment results in a behavioral neuroprotection against kainic acid-induced neurotoxicity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 12659170     DOI: 10.1016/s0024-3205(00)00658-5

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  11 in total

Review 1.  Neuroprotection as a Potential Therapeutic Perspective in Neurodegenerative Diseases: Focus on Antiepileptic Drugs.

Authors:  D Caccamo; L R Pisani; P Mazzocchetti; R Ientile; P Calabresi; F Pisani; C Costa
Journal:  Neurochem Res       Date:  2015-12-31       Impact factor: 3.996

2.  Studies of the reproduction of long-term memory during exposure to kainic Acid.

Authors:  V I Arkhipov; N A Shevchenko
Journal:  Neurosci Behav Physiol       Date:  2005-10

3.  Spatial memory is enhanced in long-living Ames dwarf mice and maintained following kainic acid induced neurodegeneration.

Authors:  Sunita Sharma; James Haselton; Sharlene Rakoczy; Stephanie Branshaw; Holly M Brown-Borg
Journal:  Mech Ageing Dev       Date:  2010-06-16       Impact factor: 5.432

Review 4.  Promise of resveratrol for easing status epilepticus and epilepsy.

Authors:  Ashok K Shetty
Journal:  Pharmacol Ther       Date:  2011-04-28       Impact factor: 12.310

Review 5.  Anaesthetic-related neuroprotection: intravenous or inhalational agents?

Authors:  Daniela Schifilliti; Giovanni Grasso; Alfredo Conti; Vincenzo Fodale
Journal:  CNS Drugs       Date:  2010-11       Impact factor: 5.749

Review 6.  Progress in neuroprotective strategies for preventing epilepsy.

Authors:  Munjal M Acharya; Bharathi Hattiangady; Ashok K Shetty
Journal:  Prog Neurobiol       Date:  2007-12-08       Impact factor: 11.685

Review 7.  Implications of decreased hippocampal neurogenesis in chronic temporal lobe epilepsy.

Authors:  Bharathi Hattiangady; Ashok K Shetty
Journal:  Epilepsia       Date:  2008-06       Impact factor: 5.864

8.  Antioxidant, anticonvulsive and neuroprotective effects of dapsone and phenobarbital against kainic acid-induced damage in rats.

Authors:  Araceli Diaz-Ruiz; Marisela Mendez-Armenta; Sonia Galván-Arzate; Joaquín Manjarrez; Concepción Nava-Ruiz; Iván Santander; Gustavo Balderas; Camilo Ríos
Journal:  Neurochem Res       Date:  2013-06-01       Impact factor: 3.996

Review 9.  Neurogenesis in the Hippocampus of Patients with Temporal Lobe Epilepsy.

Authors:  Qin Zhong; Bo-Xu Ren; Feng-Ru Tang
Journal:  Curr Neurol Neurosci Rep       Date:  2016-02       Impact factor: 5.081

Review 10.  Concise review: prospects of stem cell therapy for temporal lobe epilepsy.

Authors:  Ashok K Shetty; Bharathi Hattiangady
Journal:  Stem Cells       Date:  2007-06-28       Impact factor: 6.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.